Vorapaxar is primarily used in the prevention of thrombotic cardiovascular events. It is specifically prescribed to reduce the risk of heart attack, stroke, and cardiovascular death in patients with a history of heart attack or peripheral arterial disease. The drug works by selectively antagonizing the protease-activated receptor-1 (PAR-1) on platelets, thereby inhibiting platelet aggregation, which helps prevent the formation of blood clots that can lead to serious cardiovascular events. It is often used in combination with other antiplatelet therapies, such as aspirin or clopidogrel, to enhance its effectiveness. However, it is not recommended for patients with a history of stroke, transient ischemic attack, or intracranial hemorrhage, as it may increase the risk of bleeding. Vorapaxar is typically administered orally, and its use requires careful consideration of the patient’s medical history and risk factors for bleeding.